UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049978
Receipt number R000056927
Scientific Title A multicenter observational study for measurement of SNPs in participants of the Japan Polyp Study Cohort
Date of disclosure of the study information 2023/01/10
Last modified on 2023/01/06 17:01:56

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A multicenter observational study for measurement of SNPs in participants of the Japan Polyp Study Cohort

Acronym

JPS Cohort SNP measurement study

Scientific Title

A multicenter observational study for measurement of SNPs in participants of the Japan Polyp Study Cohort

Scientific Title:Acronym

JPS Cohort SNP measurement study

Region

Japan


Condition

Condition

Colorectal cancer

Classification by specialty

Gastroenterology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To examine risk factors for the development of colorectal carcinoma focusing on single-nucleotide polymorphisms (SNPs) in patients with a history of colorectal cancer and assess how the SNPs modify the effectiveness of aspirin in preventing colorectal cancer using the data from J-CAPP Study II as a historical control.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Others

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Interaction between SNPs of ALDH2 and the effectiveness of aspirin in preventing the development of index lesions (ILs: cancers, adenomas with high-grade dysplasia, and adenomas measuring >= 10 mm) at 4 years

Key secondary outcomes

1) Interaction between SNPs of ADH1B and the effectiveness of aspirin in preventing the development of ILs at 4 years
2) Interaction between SNPs of CYP2A6 and the effectiveness of aspirin in preventing the development of ILs at 4 years
3) Impacts of SNPs of ALDH2, ADH1B, and CYP2A6 on the development of ILs and adenomas within the JPS Cohort
4) Interaction between SNPs of ALDH2 and the effectiveness of aspirin in preventing the development of adenomas at 4 years
5) Interaction between SNPs of ADH1B and the effectiveness of aspirin in preventing the development of adenomas at 4 years
6) Interaction between SNPs of CYP2A6 and the effectiveness of aspirin in preventing the development of adenomas at 4 years
7) Analyses of 1) to 6) taking into account the age, sex, alcohol intake, smoking, height, and body weight
8) Analyses of 1) to 6) using the site, size, and morphology of colorectal cancer as endpoints


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Individuals who consented to participate in the JPS Cohort and have not withdrawn their consent.

Key exclusion criteria

non

Target sample size

1230


Research contact person

Name of lead principal investigator

1st name Kobayashi
Middle name
Last name Nozomu

Organization

National Cancer Center Hospital

Division name

Cancer Screening Center/ Endoscopy Division

Zip code

104-0045

Address

5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan

TEL

0335422511

Email

nokobaya@ncc.go.jp


Public contact

Name of contact person

1st name Nozomu
Middle name
Last name Kobayashi

Organization

National Cancer Center Hospital

Division name

Cancer Screening Center/ Endoscopy Division

Zip code

104-0045

Address

5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan

TEL

0335422511

Homepage URL


Email

nokobaya@ncc.go.jp


Sponsor or person

Institute

National Cancer Center Hospital

Institute

Department

Personal name



Funding Source

Organization

AMED

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Cancer Center

Address

5-1-1 Tsukiji, Chuo-ku, Tokyo

Tel

0335422511

Email

ncch-irb@ml.res.ncc.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 01 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2022 Year 11 Month 30 Day

Date of IRB

2022 Year 11 Month 30 Day

Anticipated trial start date

2023 Year 01 Month 10 Day

Last follow-up date

2025 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2027 Year 12 Month 31 Day


Other

Other related information

Methods
1) After written informed consent is obtained, 0.3 mL of blood is collected from each subject and processed using the dried blood spot method.
2) The specimens are sent by mail to the Department of Public Health, Wakayama Medical University.
3) SNPs of aldehyde dehydrogenase 2 (ALDH2), alcohol dehydrogenase 1B (ADH1B), and cytochrome P450 2A6 (CYP2A6) are measured, and the results are provided with an explanatory booklet for those who wish.
4) Other SNPs, if deemed necessary, are measured after approval by the Ethical Review Board.


Management information

Registered date

2023 Year 01 Month 06 Day

Last modified on

2023 Year 01 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056927


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name